News round-up by DDW’s Megan Thomas for 14-18 March, 2022
New breakthroughs, results, clinical trials and research exemplify the constant and forward-moving trajectory of the drug discovery and development industry in this week’s news round up.
Early-stage biopharma company Atrogi has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany to initiate a Phase I study for its drug candidate targeting type 2 diabetes.
The last patient has completed a clinical trial investigating the use of a digital platform to help patients with hypertension personalise and optimise their therapy regime.
New preclinical authentic ‘live’ virus data from Washington University School of Medicine demonstrated that Evusheld (tixagevimab co-packaged with cilgavimab) retains potent neutralising activity against the emerging and highly transmissible Omicron SARS-CoV-2 BA.2 subvariant.
4D Pharma has announced positive interim results for its Phase I/II study of a combination therapy targeting the treatment of renal cell carcinoma.
Research has shown which statins people with diabetes should be taking if they want to lower their “bad” cholesterol and prevent cardiovascular disease. An analysis of data from 42 clinical trials showed the effectiveness of seven statins in lowering all types of bad cholesterol for patients with diabetes.